EMD Millipore opens GMP bioproduction facility in France

Tuesday, September 25, 2012 12:02 PM

EMD Millipore, the Billerica, Mass.-based life science division of Merck, has opened its advanced GMP bioproduction facility in Martillac, France, offering a full, single-use process train to speed a molecule’s journey to the clinic.

The site will serve users of EMD Millipore’s provantage biodevelopment and clinical supply solutions, an “open source” manufacturing option that incorporates the latest technologies for upstream and downstream processes.

The open source approach provides customers with greater control over production. With a traditional outsourcing model, the customer’s process must fit the facility and the contract manufacturer controls the process. With ProVantage Solutions, EMD Millipore develops the process for further use by the customer.  

At the new facility, EMD Millipore provides access to proven technologies, process development expertise and validation services, offering a robust template that makes it possible to go from clone selection to GMP product in only 12 months. The facility offers GMP production of mammalian proteins for pre-clinical to phase II production at the 50L to 1,250L scale. For phase III and commercial production, customers can transfer manufacturing to any location, at any scale. This freedom brings enhanced flexibility to the molecule development and the manufacturing process.

“EMD Millipore leverages more than 25 years of biomanufacturing experience with 150 molecules in our new facility in France,” said Christophe Couturier, vice president of services and solutions, EMD Millipore. “As the basis for Provantage Solutions, our experts complement customers’ internal capabilities in a way that combines the best of in-house production and conventional outsourcing. The end result is increased productivity and an accelerated time to market.”

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs